Ellen Ruth Laird

USPTO Granted Patents = 35 (Patent Applications = 6)

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 7)

Average Co-Inventor Count = 7.5

ph-index = 6

Forward Citations = 198(Granted Patents)

Location History:

Mystic, CT (US) (2000 - 2002)
Longmont, CT (US) (2003)
Longmont, CO (US) (2004 - 2023)
Boulder, CO (US) (2011 - 2023)

Company Filing History:

Takeda Pharmaceutical Company Limited

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

35 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12447153 - HER2 mutation inhibitors (2025-10-21),

2. 12303509 - Compounds for the treatment of BRAF-associated diseases and disorders (2025-05-20),

3. 11834453 - Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors (2023-12-05),

4. 11780835 - Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases (2023-10-10),

5. 11634409 - Compounds for the treatment of BRAF-associated diseases and disorders (2023-04-25),

6. 11414404 - Compounds for the treatment of BRAF-associated diseases and disorders (2022-08-16),

7. 11247990 - Bicyclic fused pyridine compounds as inhibitors of TAM kinases (2022-02-15),

8. 11104676 - Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases (2021-08-31),

9. 11028093 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2021-06-08),

10. 10730880 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors (2020-08-04),

11. 10189845 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2019-01-29),

12. 10017482 - Mitotic kinesin inhibitors and methods of use thereof (2018-07-10),

13. 9499503 - Mitotic kinesin inhibitors and methods of use thereof (2016-11-22),

14. 9221841 - Mitotic kinesin inhibitors and methods of use thereof (2015-12-29),

15. 9102639 - Mitotic kinesin inhibitors and methods of use thereof (2015-08-11),

Title: The Innovative Journey of Inventor Ellen Ruth Laird

Introduction:

Ellen Ruth Laird, a prolific inventor based in Longmont, CO (US), has made significant contributions to the field of pharmaceuticals with a total of 33 patents to her name. Laird's groundbreaking work has focused on developing compounds for the treatment of abnormal cell growth, including cancer.

Latest Patents:

Laird's latest patents include two notable inventions. The first patent involves Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors. This invention showcases compounds and salts that have shown promise in the treatment of abnormal cell growth. The second patent highlights Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases, offering potential in the treatment and prevention of diseases treatable with kinase inhibitors.

Career Highlights:

Throughout her esteemed career, Ellen Ruth Laird has worked with renowned companies such as Array Biopharma Inc. and Pfizer Corporation. Her innovative spirit and dedication to research have led to groundbreaking advancements in pharmaceuticals and cancer treatment. Laird's patents reflect her commitment to developing novel solutions for challenging medical conditions.

Collaborations:

Laird has collaborated with esteemed professionals in her field, including coworkers Shelley Allen and John E Robinson. These collaborations have enhanced the depth and breadth of Laird's research, leading to the successful development of pioneering pharmaceutical compounds.

Conclusion:

In conclusion, Ellen Ruth Laird stands as a trailblazing inventor whose work has significantly impacted the pharmaceutical industry. Her patents not only demonstrate her scientific acumen but also highlight her unwavering commitment to improving healthcare outcomes for those in need. Laird's innovative contributions continue to inspire advancements in the field of medicine, setting a high standard for future inventors to follow.

This text is generated by artificial intelligence and may not be accurate.